A clinical study on role of caroverine in the management of tinnitus

Abha Kumari, Sandeep Kumar


Background: Tinnitus is a perception of sound in the absence of sound stimulation and it continues to be a significant and costly health problem without a uniformly accepted treatment. The signals between the inner hair cells and the cochlear nerve fibres are most likely to be transmitted by glutamate. Hence, present study was undertaken to assess the role of caroverine which is a glutamate receptor antagonist in the management of sensory neural tinnitus.

Methods: The present study was conducted among 50 adult patient with sensory neural tinnitus divided into two groups with 25 patients in each group. In group 1 caroverine 20 mg twice daily for a period of 90 days was administered and in group 2 placebos was given. The effect of caroverine and placebo on subjective relief and objective improvement was evaluated by using THI (Tinnitus Handicap, Inventory) scoring, Tinnitus frequency matching before and after the administration of caroverine and placebo.

Results: In Group I reduction in tinnitus was seen in 16 patients (64%) in 90 days. In group II (placebo group) improvement was seen in 20% of the patient. Significant difference with respect to treatment was noted. In group 1, 8% of the patient showed complete relief from the tinnitus. 44% of the patient showed improvement below 50% whereas 12% of the patient showed improvement more than 50%.

Conclusions: Carvoverine had shown a statistically significant improvement in tinnitus management.



Caroverine, Placebo, Tinnitus

Full Text:



Heller AJ. Classification and Epidemiology of Tinnitus. Otolaryngol clin North America. 2003;36:239-48.

Han BI, Lee HW, Kim TY, Lim JS, Shin KS. Tinnitus. Characteristics, Causes, Mechanisms, and Treatments. Journal of Clinical Neurology (Seoul, Korea). 2009;5(1):11-9.

Jastreboff PJ. Phantom auditory perception (tinnitus): mechanism of generation and perception. Neurosci Res. 1990;8:221-54.

Kaltenbach JA, God frey DA Dorsal Cochlear nucleus hyperactivity and tinnitus: Are they related? Am. J. Audiol. 2008;17:S148-61.

Guitton MJ, Wany J, Puel JL. New Pharmacological strategies to restore hearing and treat tinnitus. Acta Otolaryngol. 2004;124:411-15.

Domeisen H, Hotz MA, Hausler R. Caroverine in tinnitus treatment. Acta otolaryngol. 1998;118:606-8.

Newman CW, Jacobson GP, Spitzer JB. Development of tinnitus handicap Inventory. Arch Otolaryngol Head Neck surgery. 1996;122:143-48.

Al-Swiahb J, Park SN. Characterization of tinnitus in different age groups: A retrospective review. Noise Health. 2016;18:214-9.

Martines F, Bentivegna D, Martines E, Sciacca V, Martinciglio G. Assessing audiological, pathophysiological and psychological variables in tinnitus patients with or without hearing loss. Eur Arch Otorhinolaryngol. 2010;267:1685-93.

Swain SK, Nayak S, Ravan JR, Sahu MC. Tinnitus and its current treatment–Still an enigma in medicine. Journal of the Formosan Medical Association. 2016;115(3):139-44.

Salvago P, Ballacchino A, Agrifoglio M, Ferrara S, Mucia M, Sireci F. Tinnitus patients: etiologic, audiologic and psychological profile. Acta Medica Mediterranea. 2012;28:171-5.

Ceranic B, Luxon LM. Tinnitus and other dysacusis: Scott Brown’s otorhinolaryngology and Head Neck surgery. 7th ed. Great Britain: Hooder Arnold Ltd: 2008;3:3594-619.

Denk DM, Heinzl H, Franz P, Ehvenberger K. Caroverine in tinnitus treatment. A placebo controlled blind study. Acta otolaryngologica. 1997;117:825-30.

Ehnenberger K. Topical administration of caroverine in somatic tinnitus treatment: proof-of-concept study. Int. Tinnitus J. 2005;11:34-7.

Tyler RS. The use of science to find successful tinnitus treatments. Sixth International Tinnitus Seminar; 1999:4-10.

Ehrenberger K, Felix D. Caroverine depresses the activity of cochlear glutamate receptors in guinea pigs: in vivo model for drug-induced neuroprotection? Neuropharmacology. 1992;31(12):1259-63.